다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
大韓癌韓醫學會誌 = Journal of Korean traditional oncology, v.21 no.2, 2016년, pp.37 - 50
김경순 (대구한의대학교 한의과대학 간계내과학교실) , 최홍식 (대구한의대학교 한의과대학 간계내과학교실) , 김승모 (대구한의대학교 한의과대학 간계내과학교실) , 유화승 (대전대학교 둔산한방병원 동서암센터)
AI-Helper
Ovarian cancer is the tenth most common cancer in Korean female, and the third most common cancer of female reproductive organ after breast cancer and uterine cervical cancer. In spite of develop of conventional treatment, high modality of ovarian cancer comes from difficulty of an early diagnosis. ...
| 핵심어 | 질문 | 논문에서 추출한 답변 |
|---|---|---|
| 난소암의 일차 항암화학요법에 쓰이는 paclitaxel의 부작용은 무엇인가요? | 대부분의 암환자들은 항암화학요법으로 동안 피로, 기억력 감퇴, 슬픔, 식욕저하, 통증, 보행의 어려움과 구강건조, 수면장애, 오심/구토, 사지 무감각과 같은 증상을 경험한다고 알려져 있다7). 난소암의 일차 항암화학요법에 쓰이는 paclitaxel은 골수억제증상, 말초신경독성, 과민증과 탈모 등을 유발하며 carboplatin또는 cisplatin은 투여 직후부터 48시간 이내에 심한 오심/구토, 골수억제로 인한 호흡기 감염증상, 기관지 분비물 증가, 설사, 피부의 발적과 구강점막 궤양 증상이 나타날 수 있다8). 항암화학요법 주기와 약물 누적용량에 따라 증상의 중증도가 심화될 수 있으며, 치료의 결과 발생하는 증상은 단독으로 나타나지 않고 2개～3개 또는 그 이상 함께 나타나 클러스터를 형성한다8). | |
| 난소암의 종류는 어떻게 되나요? | 난소암은 가장 치명적인 부인암으로서 선별검사와 증상을 바탕으로 한 조기 발견이 효과적으로 사망률을 낮추지 못하는 것으로 알려져 있다. 난소암은 그 종류가 다양하여, 85% 이상을 차지하는 상피성난소암(Epithelial tumors)과 그 외 생식세포종양(Germ cell tumors) 그리고 성삭간질종양(Sex cord-stromal tumors)으로 분류된다. 상피성난소암은 최근 발암의 기원, 분자생물학적 발생기전, 임상 양상 등을 바탕으로 1형과 2형으로 분류되고 있다. | |
| 상피성난소암이 병기 IA나 IB 일 때, 조직분화도에 따라서 수술 후 보조 항암화학요법을 어떻게 쓰는가? | 대부분의 상피성난소암 환자는 수술 후 보조항암화학요법을 받게 된다. 그러나 병기 IA 혹은 IB이면서 조직분화도 1인 경우에는 수술만으로 90% 이상의 생존율을 보이므로 보조 항암화학요법 없이 경과 관찰한다. 병기 IA 혹은 IB이면서 조직분화도 2인 경우에는 추가 치료 없이 추적관찰을 시행하거나 taxane/platinum 항암화학요법을 3-6회 투여한다. 그러나 병기 IA 혹은 IB이면서 분화도가 3인 경우 (투명세포암 모두 포함)와 모든 IC의 경우에는 분화도와 상관없이 taxane/platinum 항암화학요법을 3-6회 투여하여야 한다. |
국가암정보센터. http://www.cancer.go.kr/mbs/cancer/subview.jsp?idcancer_040101000000.
Chereau E, Ballester M, Rouzier R, Coutant C, Darai E. Advanced ovarian cancer: criteria of resectability. Bulletin du cancer. 2009;96(12):1189-97.
Baiocchi G, Cestari LA, Macedo MP, Oliveira RA, Fukazawa EM, Faloppa CC, et al. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection. Journal of surgical oncology. 2011;104(3):250-4.
Picaud L, Thibault B, Mery E, Ouali M, Martinez A, Delord JP, et al. Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression. Journal of ovarian research. 2014;7:40.
Menzies D. Postoperative adhesions: their treatment and relevance in clinical practice. Annals of the Royal College of Surgeons of England. 1993;75(3):147-53.
Ushijima K. Treatment for recurrent ovarian cancer-at first relapse. Journal of oncology. 2010;2010:497429.
Kim KD, Kang SB, Chung HH, Kim JW, Park NH, Song YS, et al. Clinical characteristics of ovarian cancer patients who underwent enterostomy. Korean journal of obstetrics and gynecology. 2008;51(7):732-7.
Choi JH, Suh MJ, Park DC. The correlation of clusterin binding affinity to chemotherapeutic agents with chemoresistance in ovarian cancer cells. Korean journal of obstetrics and gynecology. 2008;51(7):738-43.
난소암 진료권고안(ver. 3.0). 부인종양학회. 2015. http://www.sgo.or.kr/community/pdf/guide_01_2016_03.pdf.
林洪生. 惡性腫瘤中醫診療指南. 北京, 人民衛生出版社, p. 448-70, 2014.
Walker JL, Powell CB, Chen LM, Carter J, Jump VL, Parker LP, et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer. 2015;121(13):2108-20.
Falconer H, Yin L, Gronberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst. 2015; 107(2):dju410.
Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol. 2013;121(1):14-24.
Kim SC. Recent advances in ovarian cancer treatment. J Korean Med. 2016;59(3):164-6.
Chang SJ. Surgical management of ovarian cancer. J Korean Med Assoc 2016;59:167-74.
Lim MC, Park SY. Chemotherapy for ovarian cancer. J Korean Med Assoc 2016;59:175-9.
Kim JW. Targeted therapy and immunotherapy in ovarian cancer. J Korean Med Assoc. 2016;59:180-8.
Schlaerth AC, Chi DS, Poynor EA, Barakat RR, Brown CL. Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. Oct 2009;19(7):1199-204.
Kajiyama H, Shibata K, Mizuno M, et al. Fertility-sparing surgery in young women with mucinous adenocarcinoma of the ovary. Gynecologic oncology. 2011;122(2):334-8.
Ditto A, Martinelli F, Lorusso D, Haeusler E, Carcangiu M, Raspagliesi F. Fertility sparing surgery in early stage epithelial ovarian cancer. Journal of gynecologic oncology. Oct 2014;25(4):320-7.
Oshita T, Itamochi H, Nishimura R, et al. Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group. International journal of clinical oncology. 2013;18(6):1107-13.
Svolgaard O, Lidegaard O, Nielsen MLS, Nedergaard L, Mosgaard BJ, Lidang M, et al. Lymphadenectomy in surgical stage I epithelial ovarian cancer. Acta obstetricia et gynecologica Scandinavica. 2014;93(3):256-60.
Chi DS, Eisenhauer EL, Zivanovic O, Sonodaa Y, Abu-Rustuma NR, Levinea DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009; 114(1):26-31.
Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santin AD, et al. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). Journal of surgical oncology. 2013;107(2):195-200.
Fago-Olsen CL, Ottesen B, Kehlet H, Antonsena SL, Christensenc IJ, Markauskasd A, et al. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study. Gynecologic oncology. 2014;132(2):292-8.
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer(CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249-57.
Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson J, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-53.
Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki T, et al. Dosedense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331-8.
Pignata S, Scambia G, Katsaros D, Isonishi S, Jobo T, Aoki D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. The Lancet. Oncology. 2014;15(4):396-405.
van der Burg ME, Onstenk W, Boere IA, Look M, Ottevanger PB, de Gooyer D, et al. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. European journal of cancer. 2014;50(15):2592-601.
Walker JL, Armstrong DK, Huang HQ, Jeffrey F, Kenneth W, Robert BA, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100(1):27-32.
Mobus V, Wandt H, Frickhofen N, Bengala C, Kim C, Rainer K, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol. 2007;25(27):4187-93.
Aghajanian C, Blank SV, Goff BA. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(17):2039-45.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(13):1302-8.
박재갑, 방영주, 하성환. 종양학. 서울, 일조각, p. 561-80, 2012.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.